

Programme

Wednesday 26 March

14.00h Opening of the Workshop

Session 1 Epidemiology of HIV resistance

- | | | |
|--------|---|----------------|
| 14.15h | Invited lecture : Surveillance monitoring of HIVDR in low-middle income countries: The WHO recommended strategy | A. De Luca |
| 14.45h | Invited lecture : Patient follow up and resistance testing in resource poor settings | H. Agostinho |
| 15.15h | Transmission and persistence of HIV-1 with thymidine analogue resistance mutations in HIV-1 infected patients with documented date of infection | C. Kuecherer |
| 15.25h | Declining of HIV-1 drug resistance in treatment-failing patients: a potential association with more effective antiretroviral regimens | M. Santoro |
| 15.35h | Viral re-suppression and emergence of drug resistance following interruption of a suppressive NNRTI-containing regimen in the SMART study | Z. Fox |
| 15.45h | Worldwide comparison of mutational patterns in studies on transmission of drug resistant HIV-1 across the World. Update on the results of the WATCH study | D. Frentz |
| 15.55h | Trends in transmitted drug-resistant HIV-1 in Europe (Sept 2002 – Dec 2005) | J. Vercauteren |
| 16.05h | Incidence of antiretroviral drug resistance in HIV-1 infected patients in Denmark 1998-2005 | A. Audelin |
| 16.15h | Trends in transmitted antiretroviral resistance in London | C. Booth |
| 16.30h | Coffee break | |

Session 2 Mechanism of HIV Resistance

- | | | |
|--------|--|---------------|
| 17.00h | Biological basis for the preference of subtype C viruses to mutate along the K65R pathway | M. Wainberg |
| 17.15h | Computational analysis of covariation and interactions between HIV-1 reverse transcriptase and Integrase | O. Sander |
| 17.30h | A novel pathway involving protease M46I & L76V and gag A431V explaining failure to Lopinavir/r | M. Nijhuis |
| 17.45h | T-20 induces mutations also in the regulatory protein rev | V. Svicher |
| 18.00h | In Silico Study suggests that Raltegravir-resistant mutations modify the DNA recognition properties of HIV-1 Integrase | L. Tchertanov |
| 18.15h | Welcome drinks & Poster Viewing Sessions 1& 2 | |

Thursday 27 March

Session 3 Resistance to Antiretroviral Drugs & Clinical Implications (1)

- | | | |
|---------------|---|------------------|
| 08.30h | The impact of resistance testing in antiretroviral drug-naïve patients: Does it guide optimal therapy selection and improve virological outcomes? | AM. Geretti |
| 08.45h | Nine-Year Trends in Clinically-Relevant Reduced HIV-1 Susceptibility to Antiretrovirals | P. Sista |
| 09.00h | Are current or archived resistance mutations predictive of treatment failure in heavily pre-treated HIV patients? | M. Zaccarelli |
| 09.15h | HIV drug resistance has a limited impact on the effectiveness of Pre-Exposure Prophylaxis (PrEP) | D. van de Vijver |
| 09.30h | Twenty-four months of intermittent HAART do not modify drug-associated resistance pattern in proviral HIV-1 DNA | L. Palmisano |
| 09.45h | Discussion | |
| 10.00h | Coffee break + Poster Viewing session 3 | |

Session 3 Resistance to Antiretroviral Drugs & Clinical Implications (2)

- | | | |
|---------------|---|----------------|
| 11.00h | Invited lecture: Resistance to new PI and NNRTI | J. Schapiro |
| 11.30h | Failure of antiretroviral therapy and HIV cleavage site mutations | J. Verheyen |
| 11.45h | Combined PI and NNRTI resistance analysis of the pooled DUET trial: towards a regimen-based resistance interpretation | J. Schapiro |
| 12.00h | Emerging mutations in patients with virological failure on TMC125 in the DUET-1 and DUET-2 clinical trials | J. Vingerhoets |
| 12.15h | Drug Resistance Profiles of HIV Integrase Gene in Patients Failing Raltegravir-salvage Therapy | C. Charpentier |
| 12.30h | Evolution of HIV-1 pol under HAART does not restrict fitness progression of HIV-1 integrase | MJ. Buzon |
| 12.45h | Discussion | |
| 13.00h | Lunch | |

Session 3 Resistance to Antiretroviral Drugs & Clinical Implications (3)

- | | | |
|---------------|--|--------------|
| 14.00h | Invited lecture: Entry Inhibitors | D. Kuritzkes |
| 14.30h | Dual-tropic virus clones from patients enrolled in the MOTIVATE studies, may respond differently in vivo to Maraviroc based on their V3 loop sequence. | M. Lewis |
| 14.45h | Characterization of Maraviroc resistance in patients failing treatment with CCR5-tropic virus in MOTIVATE 1 and MOTIVATE 2 (24 week analysis) | J. Mori |
| 15.00h | Coffee break + Poster viewing sessions 4, 5& 6 | |

**Round Table: Resistance genotyping for HIV transmission investigation:
Ethical and Legal Implications**

16.00h	Molecular epidemiology as a forensic technique for HIV transmission investigation	Jan Albert
16.15h	Criminalization of HIV transmission	M. Weait
16.30h	How do police, accuser and accused view transmission and HIV science issues in prosecutions and how can this affect justice?	L. Powers
16.45h	Considerations for invited experts in court cases on transmission of HIV'	AM. Geretti
17.00h	Guidelines for the use of HIV molecular epidemiology for HIV transmission investigation in forensic context	AM Vandamme
17.30h	Discussion	
18.00h	End of plenary session	

Friday 28 March

Session 4 Diagnostic Technology

08.30h	Invited lecture: Pyro Sequencing for Drug Resistance	J. Albert
09.00h	A genotypic assay for the amplification and sequencing of integrase from diverse human immunodeficiency virus type 1 group M subtypes	K. Van Laethem
09.15h	Development of a commercial assay for genotyping HIV-1 Integrase	N. Marlowe
09.30h	A novel recombinant virus assay for measuring drug susceptibility to PI, RTI, INI and EI in HIV-1 group M subtypes	K. Covens
09.45h	Detection of CXCR4-using HIV by the Trofile and MT2 assays in clinical samples	A. Van 't Wout
10.00h	CXCR4 using HIV-1 strains are more abundant in PBMC than in plasma	C. Verhofstede
10.15h	Resistance testing of plasma HIV-1 RNA and whole blood proviral DNA in patients with low viral load: feasibility and predictivity	M. Colafigli
10.30h	Coffee break	

Session 5 Interpretation approaches

11.15h	Updated clinical cut-offs for the vircoTYPE HIV-1 resistance analysis	L. Bachelier
11.30h	The impact of genotypic resistance testing on the composition of first line therapy in the German HIV-Seroconverter Cohort - Wait and see vs. hit hard and early? -	B. Bartmeyer
11.45h	Improving the prediction of virologic response to tipranavir: the development of a tipranavir weighted mutation score	J. Scherer
12.00h	Phenotypic evaluation of resistance to tipranavir (TPV) in non-B subtypes of HIV-1 possibly resistant according to genotype interpretation rules	J-D. Poveda
12.15h	Development and performance of a trial-specific genotypic sensitivity score based on RESIST data that incorporates treatment history in addition to predicted susceptibility	D. Hall

- 12.30h The EuResist approach for predicting response to anti HIV-1 therapy A. Altmann
- 12.45h Comparison of the slopes of HIV-1 drug response curves to antiretrovirals - Addressing NRTI drug potency H. Walter

13.00h Lunch

Round Table: Tropism Assays

- 14.00h Invited lecture: Overview on genotypic and phenotypic assays for Viral tropism determination J. Izopet
- 14.45h Update on consensus meeting AM. Vandamme

Session 6 Relation between HIV Variability and Resistance

- 15.00h Invited lecture: Update on HIV-2 infection F. Brun-Vezinet
- 15.20h Minor differences in drug susceptibility of "wild-type" HIV-1 of subtypes B, C, D, A1, CRF01_AE and CRF02_AG M. Van Houtte
- 15.30h Exploring the effect of HIV-1 subtype on virological and immunological responses to first-line HAART A. Geretti
- 15.40h Demographic determinants of HIV-1 subtype distribution in Europe A. Abecasis
- 15.50h Demographic analysis of a new HIV-1 B/F1 unique recombinant form outbreak in Luxembourg D. Struck

16.00h Coffee break

Session 7 Resistance to other viruses

- 16.30h Invited lecture: Update on treatment options for HEP-B patients V. Soriano
- 17.00h Invited lecture: Tamiflue resistance in Influenza infected patients t.b.c

17.30h Closure of the Workshop

19.00h Departure for Award Dinner

Saturday 29 March

09.00 - 09.30h Picking up posters